ES2990113T3 - Conjugados de adyuvantes de anticuerpos - Google Patents

Conjugados de adyuvantes de anticuerpos Download PDF

Info

Publication number
ES2990113T3
ES2990113T3 ES17825059T ES17825059T ES2990113T3 ES 2990113 T3 ES2990113 T3 ES 2990113T3 ES 17825059 T ES17825059 T ES 17825059T ES 17825059 T ES17825059 T ES 17825059T ES 2990113 T3 ES2990113 T3 ES 2990113T3
Authority
ES
Spain
Prior art keywords
shows
rituximab
immunoconjugate
hours
unconjugated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17825059T
Other languages
English (en)
Spanish (es)
Inventor
Michael Nathaniel Alonso
Edgar George Engleman
Shelley Erin Ackerman
Justin Kenkel
Arthur Lee
David Y Jackson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Board Of Trustees Of Leland Stanfordjunior Univ
Bolt Biotherapeutics Inc
Original Assignee
Board Of Trustees Of Leland Stanfordjunior Univ
Bolt Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Trustees Of Leland Stanfordjunior Univ, Bolt Biotherapeutics Inc filed Critical Board Of Trustees Of Leland Stanfordjunior Univ
Application granted granted Critical
Publication of ES2990113T3 publication Critical patent/ES2990113T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES17825059T 2016-07-07 2017-07-07 Conjugados de adyuvantes de anticuerpos Active ES2990113T3 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662359627P 2016-07-07 2016-07-07
US201662359626P 2016-07-07 2016-07-07
US201662432530P 2016-12-09 2016-12-09
US201662433742P 2016-12-13 2016-12-13
US201762522623P 2017-06-20 2017-06-20
US201762526306P 2017-06-28 2017-06-28
PCT/US2017/041268 WO2018009916A1 (en) 2016-07-07 2017-07-07 Antibody adjuvant conjugates

Publications (1)

Publication Number Publication Date
ES2990113T3 true ES2990113T3 (es) 2024-11-28

Family

ID=60912313

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17825059T Active ES2990113T3 (es) 2016-07-07 2017-07-07 Conjugados de adyuvantes de anticuerpos

Country Status (11)

Country Link
US (4) US10675358B2 (enExample)
EP (1) EP3484518B1 (enExample)
JP (3) JP7011764B2 (enExample)
KR (2) KR102726248B1 (enExample)
CN (2) CN109843327B (enExample)
AU (1) AU2017292934B9 (enExample)
BR (1) BR112019000071A2 (enExample)
CA (1) CA3029902A1 (enExample)
ES (1) ES2990113T3 (enExample)
IL (1) IL263616B2 (enExample)
WO (1) WO2018009916A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017292934B9 (en) 2016-07-07 2024-08-29 Bolt Biotherapeutics, Inc. Antibody adjuvant conjugates
WO2018079740A1 (ja) 2016-10-28 2018-05-03 東レ株式会社 癌の治療及び／又は予防用医薬組成物
WO2018112108A1 (en) * 2016-12-13 2018-06-21 Bolt Biotherapeutics, Inc. Antibody adjuvant conjugates
WO2019222676A1 (en) * 2018-05-17 2019-11-21 Bolt Biotherapeutics, Inc. Immunoconjugates
AU2019330977A1 (en) * 2018-08-29 2021-04-15 Bolt Biotherapeutics, Inc. Immunoconjugates targeting EGFR
JP2022500414A (ja) 2018-09-12 2022-01-04 シルバーバック セラピューティックス インコーポレイテッド 免疫刺激性コンジュゲートにより疾患を処置する方法および組成物
JP7695885B2 (ja) * 2019-02-12 2025-06-19 アンブルックス，インコーポレイテッド 抗体－ｔｌｒアゴニストコンジュゲートを含有する組成物、その方法、及び使用
WO2020190734A1 (en) * 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting pd-l1
US20220226492A1 (en) * 2019-03-15 2022-07-21 Bolt Biotherapeutics, Inc. Immunoconjugates Targeting HER2
WO2020190762A1 (en) * 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Macromolecule-supported tlr agonists
EP3937984A1 (en) * 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
US20220152215A1 (en) * 2019-03-15 2022-05-19 Bolt Biotherapeutics, Inc. Immunoconjugates Targeting CEA
WO2021067644A1 (en) 2019-10-01 2021-04-08 Silverback Therapeutics, Inc. Combination therapy with immune stimulatory conjugates
US11179473B2 (en) 2020-02-21 2021-11-23 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
KR20220145871A (ko) * 2020-02-25 2022-10-31 볼트 바이오테라퓨틱스 인코퍼레이티드 암 치료 방법
US12428461B2 (en) 2020-06-03 2025-09-30 Ascendis Pharma Oncology Division A/S Treating cancer with a conjugate comprising an IL-2 moiety
CN116209678A (zh) 2020-07-01 2023-06-02 安尔士制药公司 抗asgr1抗体缀合物及其用途
EP4196168A1 (en) * 2020-08-13 2023-06-21 Bolt Biotherapeutics, Inc. Pyrazoloazepine immunoconjugates, and uses thereof
JP2023540701A (ja) 2020-08-28 2023-09-26 アセンディス ファーマ オンコロジー ディヴィジョン エー／エス グリコシル化ｉｌ－２タンパク質及びその使用
IL303350A (en) 2020-12-04 2023-08-01 Macrogenics Inc Pharmaceutical compositions of a her2/neu antibody and use of the same
US20220195066A1 (en) * 2020-12-11 2022-06-23 Bolt Biotherapeutics, Inc. Anti-cea immunoconjugates, and uses thereof
JP2024539993A (ja) 2021-10-29 2024-10-31 ボルト バイオセラピューティクス、インコーポレーテッド システイン変異抗体を含むｔｌｒアゴニスト免疫複合体、及びその使用
IL312728A (en) 2021-11-30 2024-07-01 Daiichi Sankyo Co Ltd Protease-cleavable masked antibodies
CA3251410A1 (en) 2022-02-09 2025-07-08 Daiichi Sankyo Co Ltd Masked antibody sensitive to the environment and its use
WO2023168455A2 (en) * 2022-03-04 2023-09-07 D2M Biotherapeutics Limited Anti-lilrb1/2 antibodies and uses thereof
AR130111A1 (es) * 2022-08-03 2024-11-06 Seagen Inc Conjugados de anticuerpo y fármaco inmunoestimuladores
WO2024102078A1 (en) * 2022-11-10 2024-05-16 Nanyang Technological University Heterobifunctional linkers and bioconjugate molecules
KR20250128394A (ko) 2022-11-30 2025-08-27 리제너론 파마슈티칼스 인코포레이티드 Tlr7 작용제 및 이의 항체-약물-접합체
AU2024270185A1 (en) 2023-05-09 2025-11-06 Ascendis Pharma Oncology Division A/S Novel cancer treatments with il-2 conjugates
WO2025015234A2 (en) * 2023-07-13 2025-01-16 Ltz Therapeutics Inc. Multispecific antibodies and uses thereof
WO2025031923A1 (en) 2023-08-04 2025-02-13 Sanofi Imidazo[4,5-d]pyridazine compounds and conjugates thereof, their preparation, and their therapeutic applications

Family Cites Families (388)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH653021A5 (fr) 1981-04-24 1985-12-13 Delalande Sa Derives piperidino, piperazino et homopiperazino, n-substitues par un groupe heterocyclique aromatique, leur procede de preparation et composition therapeutique les contenant.
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
WO1990014844A2 (en) 1989-06-06 1990-12-13 Neorx Corporation Sugars as cleavable linkers for the delivery and release of agents in native form
US5650150A (en) 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
DE69434279T2 (de) * 1993-12-09 2006-04-06 Centro De Inmunologia Molecular Impfstoff, der einen menschlichen autologenen epidermalen Wachstumsfaktor enthält und dessen Verwendung
EP0894797A4 (en) 1997-01-09 2001-08-16 Terumo Corp NEW AMID DERIVATIVES AND INTERMEDIATES ON YOUR SYNTHESIS
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US20090208418A1 (en) * 2005-04-29 2009-08-20 Innexus Biotechnology Internaltional Ltd. Superantibody synthesis and use in detection, prevention and treatment of disease
US20020155108A1 (en) 1998-05-04 2002-10-24 Biocrystal, Ltd. Method for ex vivo loading of antigen presenting cells with antigen, and a vaccine comprising the loaded cells
SE513217C2 (sv) 1999-06-03 2000-07-31 Jan Folke Wallenius Förfarande och anordning för att under färd bestämma friktionen mellan vägbanan och ett fordons hjul
FI107193B (fi) 1999-06-03 2001-06-15 Rouvari Oy R Mittausanturi
GB2354828A (en) 1999-06-04 2001-04-04 Cheong Cheun Edmund Choi Apparatus and method for testing an impervious surface
US6451810B1 (en) 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6573273B1 (en) 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
EP2264072A1 (en) 2000-04-13 2010-12-22 The Rockefeller University Enhancement of antibody-mediated cytotoxicity.
WO2001097843A2 (en) 2000-06-22 2001-12-27 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
CN1549726A (zh) * 2000-07-31 2004-11-24 耶鲁大学 先天性免疫系统指导的疫苗
MXPA03003632A (es) 2000-10-24 2003-09-10 Immunex Corp Metodo para tratamiento de tumores usando terapia de combinacion.
US20060142202A1 (en) 2000-12-08 2006-06-29 3M Innovative Properties Company Compositions and methods for targeted delivery of immune response modifiers
US20020110840A1 (en) 2000-12-08 2002-08-15 3M Innovative Properties Company Screening method for identifying compounds that selectively induce interferon alpha
EP1719511B1 (en) 2001-11-16 2008-12-10 3M Innovative Properties Company N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide, a pharmaceutical composition comprising the same and use thereof
DK1450804T3 (da) 2001-11-29 2009-01-05 3M Innovative Properties Co Farmaceutiske formulelringer, der omfatter et immunsvarmodificerende middel
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
PT3483183T (pt) 2002-03-01 2021-06-02 Immunomedics Inc Imunoconjugado compreendendo anticorpos rs7 humanizados
ATE488246T1 (de) 2002-08-15 2010-12-15 3M Innovative Properties Co Immunstimulatorische zusammensetzungen und verfahren zur stimulierung einer immunantwort
US6924154B2 (en) 2002-08-20 2005-08-02 Quest Diagnostics Investments Incorporated Hydrophilic chemilumescent acridinium labeling reagents
US20040101909A1 (en) 2002-08-20 2004-05-27 Hema-Quebec, 2535 Boul. Laurier, Ste-Foy, Quebec, Canada G1V 4M3 Purification of polyreactive autoantibodies and uses thereof
EP1542688A4 (en) 2002-09-26 2010-06-02 3M Innovative Properties Co 1H-imidazo dimers
AU2003287316A1 (en) 2002-12-11 2004-06-30 3M Innovative Properties Company Assays relating to toll-like receptor activity
AU2003287324A1 (en) 2002-12-11 2004-06-30 3M Innovative Properties Company Gene expression systems and recombinant cell lines
US7091214B2 (en) 2002-12-20 2006-08-15 3M Innovative Properties Co. Aryl substituted Imidazoquinolines
EP1578419A4 (en) 2002-12-30 2008-11-12 3M Innovative Properties Co IMMUNOSTIMULATING COMBINATIONS
US7375180B2 (en) 2003-02-13 2008-05-20 3M Innovative Properties Company Methods and compositions related to IRM compounds and Toll-like receptor 8
EP1599726A4 (en) 2003-02-27 2009-07-22 3M Innovative Properties Co SELECTIVE MODULATION OF TLR-MEDIATED BIOLOGICAL ACTIVITY
EP1613956A2 (en) 2003-03-25 2006-01-11 3M Innovative Properties Company Selective activation of cellular activities mediated through a common toll-like receptor
EP1617872A4 (en) 2003-04-10 2011-09-07 3M Innovative Properties Co METHODS AND COMPOSITIONS FOR ENHANCING AN IMMUNE RESPONSE
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
WO2004108072A2 (en) 2003-04-10 2004-12-16 3M Innovative Properties Company Delivery of immune response modifier compounds using metal-containing particulate support materials
US20040214851A1 (en) 2003-04-28 2004-10-28 3M Innovative Properties Company Compositions and methods for induction of opioid receptors
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
MY157827A (en) 2003-06-27 2016-07-29 3M Innovative Properties Co Sulfonamide substituted imidazoquinolines
US20050070460A1 (en) 2003-08-05 2005-03-31 3M Innovative Properties Company Infection prophylaxis using immune response modifier compounds
PL1653959T3 (pl) 2003-08-14 2015-10-30 3M Innovative Properties Co Modyfikatory odpowiedzi immunologicznej modyfikowane lipidami
WO2005019429A2 (en) 2003-08-22 2005-03-03 Potentia Pharmaceuticals, Inc. Compositions and methods for enhancing phagocytosis or phagocyte activity
US7897597B2 (en) 2003-08-27 2011-03-01 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
US20150071948A1 (en) 2003-09-26 2015-03-12 Gregory Alan Lazar Novel immunoglobulin variants
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
WO2005051324A2 (en) 2003-11-25 2005-06-09 3M Innovative Properties Company Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2005065678A1 (en) 2003-12-30 2005-07-21 3M Innovative Properties Company Immunomodulatory combinations
WO2005067980A2 (en) 2004-01-12 2005-07-28 Pointilliste, Inc. Design of therapeutics and therapeutics
EP1730143A2 (en) 2004-03-24 2006-12-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2005110013A2 (en) 2004-04-09 2005-11-24 3M Innovative Properties Company Methods, compositions, and preparations for delivery of immune response modifiers
BRPI0510716A (pt) 2004-05-05 2007-11-20 Merrimack Pharmaceuticals Inc uso de um agente de ligação bi-especìfico, agente de ligação bi-especìfico, composição de um agente de ligação bi-especìfico, e, kit
US8017779B2 (en) 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
EP1765348B1 (en) 2004-06-18 2016-08-03 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
BRPI0516284A (pt) 2004-09-23 2008-09-02 Genentech Inc anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto
AU2005304771A1 (en) 2004-11-09 2006-05-18 University Of Southern California Targeted innate immunity
WO2006054310A1 (en) 2004-11-22 2006-05-26 Biosight Ltd. Activated labeling reagents and methods for preparing and using the same
EP1835935A4 (en) 2004-12-30 2009-06-17 Univ Rockefeller COMPOSITIONS AND METHODS FOR ENHANCING THE MATURATION AND FUNCTION OF DENDRITIC CELLS
AU2005322898B2 (en) 2004-12-30 2011-11-24 3M Innovative Properties Company Chiral fused (1,2)imidazo(4,5-c) ring compounds
WO2006084251A2 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune reponse modifiers
EP1845988A2 (en) 2005-02-11 2007-10-24 3M Innovative Properties Company Substituted imidazoquinolines and imidazonaphthyridines
US20100004156A1 (en) 2005-07-27 2010-01-07 Shalesh Kaushal Small Compounds That Correct Protein Misfolding and Uses Thereof
US8354249B2 (en) 2005-08-11 2013-01-15 Omrix Biopharmaceuticals Ltd. Intravenous immunoglobulin composition
ES2577514T3 (es) 2005-08-22 2016-07-15 The Regents Of The University Of California Antagonistas de TLR
AR058129A1 (es) 2005-10-21 2008-01-23 Genzyme Corp Productos terapeuticos basados en anticuerpos con actividad de adcc mejorada
EP1957099B1 (en) 2005-11-07 2015-03-25 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
US8951528B2 (en) 2006-02-22 2015-02-10 3M Innovative Properties Company Immune response modifier conjugates
WO2007103048A2 (en) 2006-03-01 2007-09-13 Regents Of The University Of Colorado Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
MX2008013993A (es) 2006-05-03 2009-05-11 Univ Colorado Combinación adyuvante sinergistica de anticuerpo agonista de cd40/interferona tipo 1, conjugados que la contienen y uso de los mismos como un terapeutico para aumentar la inmunidad celular.
US20080031887A1 (en) 2006-06-30 2008-02-07 Joseph Lustgarten Conjugates for inducing targeted immune responses and methods of making and using same
CN101511384A (zh) 2006-06-30 2009-08-19 贝勒研究院 采用GM-CSF和α干扰素制成的并装载热处理的且杀死的癌细胞的树突状细胞
GB0614098D0 (en) 2006-07-15 2006-08-23 Mnl Pharma Ltd Immune response variegation with imino sugars
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
US20080241139A1 (en) 2006-10-31 2008-10-02 Regents Of The University Of Colorado Adjuvant combinations comprising a microbial tlr agonist, a cd40 or 4-1bb agonist, and optionally an antigen and the use thereof for inducing a synergistic enhancement in cellular immunity
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
WO2008103947A2 (en) 2007-02-23 2008-08-28 Baylor Research Institute Activation of human antigen-presenting cells through clec-6
BRPI0807617A2 (pt) 2007-02-23 2014-07-22 Baylor Res Inst Aplicações terapêuticas de ativação de antígeno humano presente em células através de dectin-1.
WO2008104183A2 (en) 2007-03-01 2008-09-04 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
US8604172B2 (en) 2009-04-17 2013-12-10 Lpath, Inc. Humanized antibody compositions and methods for binding lysophosphatidic acid
EP2170931A4 (en) 2007-06-15 2010-06-30 Immurx Inc USE OF TLR AGONISTS AND / OR TYPE 1 INTERFERONS TO MITIGATE THE TOXICITY OF THERAPEUTIC REGIMES OF TNF-R AGONISTS
MX2010001194A (es) 2007-07-31 2010-07-30 Univ Louisiana State Conjugado de polipeptido-acido nucleico para inmunoprofilaxis o inmunoterapia para desordenes neoplasicos o infecciones.
US20090155289A1 (en) * 2007-11-01 2009-06-18 Steve Roberts Furin-cleavable peptide linkers for drug-ligand conjugates
US20100098657A1 (en) 2007-12-27 2010-04-22 Schafer Peter H Method of Treating Cancer with Immunomodulatory Compounds and IgG
CA2713137C (en) 2008-01-25 2017-10-24 Hadasit Medical Research Services And Development Ltd. Targeting of innate immune response to tumor site
HRP20161050T1 (hr) 2008-04-02 2016-11-18 Macrogenics, Inc. Her2/neu specifična protutijela i postupci njihovog korištenja
US8236319B2 (en) 2008-04-30 2012-08-07 Immunogen, Inc. Cross-linkers and their uses
US20090325315A1 (en) 2008-06-30 2009-12-31 Arkray, Inc. Detection method of target substance, detection reagent used for the same, and the uses thereof
CN102170907A (zh) 2008-08-05 2011-08-31 东丽株式会社 用于治疗和预防癌症的药物组合物
US20100129383A1 (en) 2008-10-03 2010-05-27 The Governors Of The University Of Alberta Bifunctional fusion molecules for the delivery of antigens to professional antigen-presenting cells
US20100150942A1 (en) 2008-12-03 2010-06-17 Cantor Thomas L Affinity purified human polyclonal antibodies and methods of making and using them
WO2010132622A2 (en) 2009-05-14 2010-11-18 The Regents Of The University Of California Anticd20-cpg conjugates and methods of treating b cell malignancies
US8524702B2 (en) 2009-08-18 2013-09-03 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
US8691809B2 (en) 2009-08-18 2014-04-08 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
EP2475391B1 (en) 2009-09-09 2018-09-12 Centrose, LLC Extracellular targeted drug conjugates
CA2772945A1 (en) 2009-09-25 2011-03-31 Xoma Technology Ltd. Screening methods
GB0917044D0 (en) 2009-09-29 2009-11-18 Cytoguide As Agents, uses and methods
GB0917054D0 (en) 2009-09-29 2009-11-11 Cytoguide As Agents, uses and methods
US8518405B2 (en) 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
WO2011096534A1 (ja) 2010-02-04 2011-08-11 東レ株式会社 癌の治療及び／又は予防用医薬組成物
PL2532366T3 (pl) 2010-02-04 2017-02-28 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
CA2788545C (en) 2010-02-04 2019-03-26 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
CA2788715C (en) 2010-02-04 2021-06-08 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
CA2788547C (en) 2010-02-04 2018-06-05 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
US9203872B2 (en) 2010-02-19 2015-12-01 Microsoft Technology Licensing, Llc Distributed connectivity policy enforcement with ICE
GB201003293D0 (en) 2010-02-26 2010-04-14 Adjuvantix Ltd Cancer vaccine
WO2011109789A2 (en) 2010-03-05 2011-09-09 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
CN103154034B (zh) 2010-04-13 2016-06-08 塞尔德克斯医疗公司 结合人cd27的抗体及其用途
US20120213771A1 (en) 2010-04-13 2012-08-23 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
EP2566518A4 (en) 2010-05-07 2013-12-25 Baylor Res Inst CROSS-LINKED MEDICATION WITH DENDRITIC CELL IMMUNORE-RECEPTORS (DCIR) OF HUMAN CD8 + T CELLS
AU2011252883B2 (en) 2010-05-14 2015-09-10 Abbvie Inc. IL-1 binding proteins
AU2011265054B2 (en) 2010-06-08 2016-09-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
EP2594589A1 (en) 2010-06-10 2013-05-22 Sapporo Medical University ANTI-Trop-2 ANTIBODY
HRP20191305T1 (hr) 2010-07-09 2019-10-18 Bioverativ Therapeutics Inc. Preradive jednolančane molekule i polipeptidi izrađeni koristeći iste
KR20130050966A (ko) 2010-07-12 2013-05-16 씨오브이엑스 테크놀로지스 아일랜드 리미티드 다기능적 항체 접합체
WO2012021834A1 (en) 2010-08-13 2012-02-16 Baylor Research Institute Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
RU2603467C2 (ru) 2010-10-01 2016-11-27 Вентиркс Фармасьютикалз, Инк. Терапевтическое применение агониста tlr и комбинированная терапия
US20120328605A1 (en) 2010-10-27 2012-12-27 Daniel Larocque Compositions and uses
EP2638066A4 (en) 2010-11-09 2015-06-03 Medimmune Llc ANTIBODY EQUIPMENT FOR HOMOGENEOUS CONJUGATION
US20120171229A1 (en) 2010-12-30 2012-07-05 Selecta Biosciences, Inc. Synthetic nanocarriers with reactive groups that release biologically active agents
AR085633A1 (es) 2011-03-08 2013-10-16 Baylor Res Inst Coadyuvantes basados en anticuerpos que son dirigidos directamente a las celulas presentadoras en antigenos
CA2831294A1 (en) 2011-03-25 2012-10-04 Baylor Research Institute Compositions and methods to immunize against hepatitis c virus
MX338353B (es) 2011-04-20 2016-04-13 Medimmune Llc Anticuerpos y otras moleculas que se unen a b7 - h1 y pd - 1.
US8728486B2 (en) 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
US20140088021A1 (en) 2011-05-27 2014-03-27 Nektar Therapeutics Water-Soluble Polymer-Linked Binding Moiety and Drug Compounds
MX355623B (es) 2011-06-03 2018-04-25 3M Innovative Properties Co Hidrazino-1h-imidazoquinolin-4-aminas y conjugados elaborados a partir de las mismas.
MX347240B (es) 2011-06-03 2017-04-20 3M Innovative Properties Co Ligadores heterobifuncionales con segmentos polietilenglicol y conjugados modificadores de la respuesta inmunitaria elaborados a partir de los mismos.
WO2012170072A1 (en) 2011-06-06 2012-12-13 Immungene, Inc. Engineered antibody-tnfsf member ligand fusion molecules
HUE033149T2 (en) 2011-08-04 2017-11-28 Toray Industries A pharmaceutical composition for the treatment and / or prevention of cancer
AU2012290949B2 (en) 2011-08-04 2017-03-02 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
PL2740795T3 (pl) 2011-08-04 2017-04-28 Toray Industries, Inc. Kompozycja lekowa do leczenia nowotworu i/lub zapobiegania nowotworowi
KR101984554B1 (ko) 2011-08-04 2019-05-31 도레이 카부시키가이샤 췌장암의 검출 방법
PL2740794T3 (pl) 2011-08-04 2018-09-28 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub profilaktyki nowotworów
KR101968498B1 (ko) 2011-08-04 2019-04-12 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
CA2844030C (en) 2011-08-04 2019-09-03 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
JP6120848B2 (ja) 2011-08-15 2017-04-26 メディミューン，エルエルシー 抗ｂ７−ｈ４抗体およびその使用
US20140363461A1 (en) 2011-09-01 2014-12-11 Fabio Bagnoli Adjuvanted formulations of staphylococcus aureus antigens
US9308253B2 (en) 2011-09-19 2016-04-12 The Johns Hopkins University Cancer immunotherapy
NL2007536C2 (en) 2011-10-05 2013-04-08 Academisch Ziekenhuis Leiden Lumc Adjuvant compound.
US20130108619A1 (en) 2011-11-02 2013-05-02 Isaac Melamed Intravenous immunoglobulin processing, diagnostic, and treatment systems and methods
EP2776070A4 (en) 2011-11-09 2016-02-10 Ascend Biopharmaceuticals Ltd IMMUNOMODULATORY CONJUGATES
SG11201401699WA (en) 2011-11-11 2014-09-26 Rinat Neuroscience Corp Antibodies specific for trop-2 and their uses
WO2013093809A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
EP3447071A1 (en) 2012-01-09 2019-02-27 Pfizer Healthcare Ireland Mutant antibodies and conjugation thereof
PT2802606T (pt) 2012-01-10 2018-07-13 Biogen Ma Inc Melhoramento do transporte de moléculas terapêuticas através da barreira hematoencefálica
US20130177574A1 (en) 2012-01-11 2013-07-11 Paul I. Terasaki Foundation Laboratory ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
MX2014009289A (es) 2012-02-01 2015-09-08 Compugen Ltd Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer.
EP2824114B1 (en) 2012-02-21 2019-05-22 Toray Industries, Inc. Pharmaceutical composition for treatment of cancer
EP2818481B1 (en) 2012-02-21 2019-08-07 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
ES2739612T3 (es) 2012-02-21 2020-02-03 Toray Industries Composición farmacéutica para el tratamiento de cáncer
ES2643241T3 (es) 2012-02-21 2017-11-21 Toray Industries, Inc. Composición medicinal para tratar y/o prevenir el cáncer
MX366864B (es) 2012-02-27 2019-07-26 Amunix Operating Inc Composiciones de conjugados de xten y métodos para realizarlas.
PL2832365T3 (pl) 2012-03-30 2018-04-30 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi wątroby
US9428581B2 (en) 2012-03-30 2016-08-30 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of gallbladder cancer
AU2013245645A1 (en) 2012-04-13 2014-11-13 Whitehead Institute For Biomedical Research Sortase- modified VHH domains and uses thereof
WO2013166110A1 (en) 2012-05-02 2013-11-07 Yale University Tlr-agonist-conjugated antibody recruiting molecules (tlr_arms)
WO2013180811A1 (en) 2012-05-30 2013-12-05 Life Technologies Corporation FLUOROGENIC pH-SENSITIVE DYES AND THEIR METHODS OF USE
EP2674170B1 (en) 2012-06-15 2014-11-19 Invivogen Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids
UA114108C2 (uk) 2012-07-10 2017-04-25 Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
CN103566377A (zh) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
US20140065096A1 (en) 2012-09-05 2014-03-06 Regen BioPharma, Inc. Cancer therapy by ex vivo activated autologous immune cells
KR102626525B1 (ko) 2013-02-08 2024-01-19 노파르티스 아게 면역접합체의 제조를 위한 항체의 변형에 사용되는 특정 부위
EP2787005A1 (en) 2013-04-02 2014-10-08 Activartis Biotech GmbH Targeted cancer immune therapy
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
US20180104349A9 (en) 2013-04-28 2018-04-19 Gang Qin Novel linker, preparation method, and application thereof
WO2015172800A1 (en) 2014-05-12 2015-11-19 Numab Ag Novel multispecific molecules and novel treatment methods based on such multispecific molecules
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
RU2678138C2 (ru) 2013-08-09 2019-01-23 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
AU2014337317A1 (en) 2013-10-15 2016-09-15 Sorrento Therapeutics Inc. Drug-conjugates with a targeting molecule and two different drugs
GB201321242D0 (en) 2013-12-02 2014-01-15 Immune Targeting Systems Its Ltd Immunogenic compound
US20150190506A1 (en) 2013-12-17 2015-07-09 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
EP3647324A1 (en) 2013-12-17 2020-05-06 F. Hoffmann-La Roche AG Methods of treating cancers using pd-1 axis binding antagonists and taxanes
HRP20190056T1 (hr) 2013-12-25 2019-02-22 Daiichi Sankyo Company, Limited Konjugat anti-trop2 antitijelo-lijek
CN104861067A (zh) * 2014-01-10 2015-08-26 博笛生物科技有限公司 用于免疫疗法的化合物和组合物
CN104861063A (zh) * 2014-01-10 2015-08-26 博笛生物科技有限公司 靶向her2阳性肿瘤的化合物和组合物
CN105899537A (zh) 2014-01-10 2016-08-24 博笛生物科技（北京）有限公司 靶向表达egfr的肿瘤的化合物和组合物
EP3096787A4 (en) 2014-01-22 2018-02-07 The Board of Trustees of the Leland Stanford Junior University Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
LT3107563T (lt) 2014-02-21 2021-07-12 Ecole Polytechnique Fédérale De Lausanne (Epfl) Epfl-Tto Gliko-nukreipiantys terapiniai agenai
JP6357327B2 (ja) 2014-03-11 2018-07-11 株式会社クレハ フッ化ビニリデン系共重合体、その製造方法、ゲル電解質および非水系電池
EP3129407A2 (en) 2014-03-12 2017-02-15 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
ES2940903T3 (es) 2014-03-19 2023-05-12 Genzyme Corp Glucomanipulación específica del sitio de restos orientadores
ES2719584T3 (es) 2014-04-11 2019-07-11 Medimmune Llc Compuestos conjugados que comprenden anticuerpos modificados por ingeniería genética con cisteína
AR100137A1 (es) 2014-04-22 2016-09-14 Hoffmann La Roche Compuestos 4-amino-imidazoquinolina
WO2015165413A1 (zh) 2014-04-29 2015-11-05 秦刚 一种新型的稳定型抗体药物耦联物及其制备方法和用途
EP3145552B1 (en) 2014-05-23 2020-03-04 Novartis AG Methods for making conjugates from disulfide-containing proteins
WO2015187637A1 (en) 2014-06-02 2015-12-10 Baylor Research Institute Methods and compositions for treating allergy and inflammatory diseases
ES2901705T3 (es) 2014-06-06 2022-03-23 Bristol Myers Squibb Co Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (GITR) y usos de los mismos
EP4001311B1 (en) 2014-07-09 2025-11-05 Birdie Biopharmaceuticals Inc. Anti-pd-l1/pd-1 combinations for treating tumors
CN112546230A (zh) 2014-07-09 2021-03-26 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
WO2016011401A1 (en) 2014-07-18 2016-01-21 Kedl Ross M Immunostimulatory combinations and use thereof
AU2015292406B2 (en) 2014-07-25 2021-03-11 Cytomx Therapeutics, Inc Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same
WO2016028149A1 (en) 2014-08-20 2016-02-25 Tu Eindhoven Ureidopyrimidone supramolecular complexes for compound delivery into cells
JP2017526673A (ja) * 2014-08-27 2017-09-14 国立大学法人九州大学 アジュバント
CN112546238A (zh) 2014-09-01 2021-03-26 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
US9884866B2 (en) 2014-09-08 2018-02-06 Regents Of The University Of Minnesota Immunomodulators and immunomodulator conjugates
JP2017535528A (ja) 2014-10-03 2017-11-30 ノバルティス アーゲー 組み合わせ治療
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
US20170304433A1 (en) 2014-10-09 2017-10-26 Wake Forest University Health Sciences Vaccine compositions and methods of use to treat neonatal subjects
GB201418004D0 (en) 2014-10-10 2014-11-26 Isis Innovation Polymer adjuvant
US9988452B2 (en) 2014-10-14 2018-06-05 Novartis Ag Antibody molecules to PD-L1 and uses thereof
EP3209334A2 (en) 2014-10-20 2017-08-30 Igenica Biotherapeutics, Inc. Novel antibody-drug conjugates and related compounds, compositions, and methods of use
WO2016064899A1 (en) 2014-10-21 2016-04-28 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
SI3221363T1 (sl) 2014-11-21 2020-09-30 Bristol-Myers Squibb Company Protitelesa proti CD73 in njihova uporaba
CA2968837A1 (en) 2014-11-25 2016-06-02 Endocyte, Inc. Methods of treating cancer by targeting tumor-associated macrophages
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
RS61470B1 (sr) 2014-12-31 2021-03-31 Checkmate Pharmaceuticals Inc Kombinovana antitumorska imunoterapija
JP6676058B2 (ja) 2015-01-14 2020-04-08 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ヘテロアリーレン架橋したベンゾジアゼピン二量体、そのコンジュゲート、ならびに製造および使用方法
TWI632160B (zh) 2015-01-16 2018-08-11 中央研究院 具有標的部分及效應部分的分子構建體
ES2761861T3 (es) 2015-01-21 2020-05-21 Univ Leland Stanford Junior Uso de agonistas de TLR y agente anti-CD47 para mejorar la fagocitosis de las células cancerosas
US20180044429A1 (en) 2015-03-09 2018-02-15 Celldex Therapeutics, Inc. Cd27 agonists
TWI703141B (zh) 2015-03-12 2020-09-01 大陸商廣東東陽光藥業有限公司 作為丙型肝炎抑制劑的化合物及其在藥物中的應用
SG11201707383PA (en) 2015-03-13 2017-10-30 Cytomx Therapeutics Inc Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
KR102749339B1 (ko) 2015-03-23 2025-01-03 바이엘 파마 악티엔게젤샤프트 항-ceacam6 항체 및 그의 용도
US20180117171A1 (en) 2015-04-01 2018-05-03 President And Fellows Of Harvard College Immunoconjugates for programming or reprogramming of cells
EP3286224A4 (en) 2015-04-22 2018-11-14 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
MX388350B (es) 2015-05-04 2025-03-19 Cytomx Therapeutics Inc Anticuerpos anti-cd166, anticuerpos anti-cd166 activables, y metodos de uso de los mismos.
EP3292151A1 (en) 2015-05-04 2018-03-14 Cytomx Therapeutics Inc. Anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereof
US10179817B2 (en) 2015-05-04 2019-01-15 Cytomx Therapeutics, Inc. Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof
US20160324981A1 (en) 2015-05-08 2016-11-10 The California Institute For Biomedical Research Liver x receptor agonists and uses thereof
US10314854B2 (en) 2015-05-15 2019-06-11 University Of Iowa Foundation Methods for treating tumors in situ including intratumor injection of cytotoxic particles and immune checkpoint blockade therapy
TWI614030B (zh) 2015-05-20 2018-02-11 免疫功坊股份有限公司 具有標的部分及效應部分的分子構建體
EP3298145A4 (en) 2015-05-22 2018-12-12 La Trobe University Method of diagnosis of breast cancer
KR20250151554A (ko) 2015-05-29 2025-10-21 제넨테크, 인크. 암에 대한 치료 및 진단 방법
SG10202008304TA (en) 2015-05-29 2020-10-29 Bristol Myers Squibb Co Antibodies against ox40 and uses thereof
US20180267024A1 (en) 2015-06-08 2018-09-20 Lophius Biosciences Gmbh Composition for determination of cell-mediated immune responsiveness
CN108026123B (zh) 2015-06-15 2021-02-05 杭州多禧生物科技有限公司 用于偶联的亲水链接体
WO2016205551A2 (en) 2015-06-16 2016-12-22 The Regents Of The University Of California Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
WO2016205566A1 (en) 2015-06-16 2016-12-22 The Regents Of The University Of California Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
US10975112B2 (en) 2015-06-16 2021-04-13 Hangzhou Dac Biotech Co., Ltd. Linkers for conjugation of cell-binding molecules
WO2016203025A1 (en) 2015-06-17 2016-12-22 Curevac Ag Vaccine composition
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
EP3317246A4 (en) 2015-07-04 2019-02-27 Suzhou M-conj Biotech Co., Ltd. SPECIFIC CONJUGATION OF A CELL BINDING MOLECULE
CN113350518A (zh) 2015-07-12 2021-09-07 杭州多禧生物科技有限公司 与细胞结合分子的共轭偶联的桥连接体
CN114591433A (zh) 2015-07-13 2022-06-07 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
CN108025051B (zh) 2015-07-29 2021-12-24 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
WO2017019894A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to lag-3
AU2016303497A1 (en) 2015-07-31 2018-03-01 Tarveda Therapeutics, Inc. Compositions and methods for immuno-oncology therapies
WO2017024296A1 (en) 2015-08-06 2017-02-09 Memorial Sloan Kettering Cancer Center Methods and compositions for tumor therapy
TW201716084A (zh) 2015-08-06 2017-05-16 葛蘭素史克智慧財產發展有限公司 組合物及其用途與治療
CN115300640A (zh) 2015-08-10 2022-11-08 杭州多禧生物科技有限公司 新型连接体及其用于药物和生物分子的特异性偶联
CN107922416B (zh) 2015-08-31 2021-07-02 3M创新有限公司 含有取代的胍基团的咪唑并[4,5-c]环化合物
WO2017040233A1 (en) 2015-08-31 2017-03-09 3M Innovative Properties Company GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS
WO2017036255A1 (en) 2015-09-01 2017-03-09 Tse-Wen Chang Molecular constructs for preventing the formation of blood clot and/or treating thrombosis
US10799580B2 (en) 2015-09-09 2020-10-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Expression vector delivery system and use thereof for inducing an immune response
RU2722149C1 (ru) 2015-09-14 2020-05-27 Пфайзер Инк. Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
US20180273948A1 (en) 2015-09-25 2018-09-27 Tarveda Therapeutics, Inc. RNAi CONJUGATES, PARTICLES AND FORMULATIONS THEREOF
EP3356371A4 (en) 2015-09-29 2020-06-24 The University of Chicago POLYMER CONJUGATE VACCINES
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
EP3370726A4 (en) 2015-11-02 2019-06-12 VentiRx Pharmaceuticals, Inc. USE OF TLR8 AGONISTS FOR CANCER TREATMENT
WO2017083525A1 (en) 2015-11-11 2017-05-18 Opi Vi- Ip Holdco Llc Composition and methods for anti-tnfr2 antibodies
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
TWI637966B (zh) 2015-11-30 2018-10-11 輝瑞股份有限公司 用於部位專一性接合之抗體和抗體片段
KR101795388B1 (ko) 2015-12-02 2017-11-09 현대자동차 주식회사 차량용 자동변속기의 유성기어트레인
US20170158772A1 (en) 2015-12-07 2017-06-08 Opi Vi - Ip Holdco Llc Compositions of antibody construct - agonist conjugates and methods of use thereof
CA3007311A1 (en) 2015-12-07 2017-06-15 Opi Vi - Ip Holdco Llc Compositions of antibody construct-agonist conjugates and methods of use thereof
CA3007671A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
WO2017117269A1 (en) 2015-12-29 2017-07-06 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for dectin-2 stimulation and cancer immunotherapy
CN115350279A (zh) 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-egfr组合
MY195114A (en) 2016-02-04 2023-01-10 Robert Yongxin Zhao Specific Conjugation Linkers, Specific Immunoconjugates Thereof, Methods of Making and uses Such Conjugates Thereof
AU2017238172B2 (en) 2016-03-21 2024-06-27 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
EP3442592A4 (en) 2016-04-13 2019-11-27 Tarveda Therapeutics, Inc. NEUROTENSIN RECEPTOR BINDING CONJUGATES AND FORMULATIONS THEREOF
SG11201808821WA (en) 2016-04-18 2018-11-29 Celldex Therapeutics Inc Agonistic antibodies that bind human cd40 and uses thereof
WO2017184735A1 (en) 2016-04-19 2017-10-26 Ifm Therapeutics, Inc Nlrp3 modulators
CN109071535B (zh) 2016-04-19 2021-10-08 先天肿瘤免疫公司 Nlrp3调节剂
IL262295B2 (en) 2016-05-09 2023-09-01 Igm Biosciences Inc Antibodies against pd–l1
TW201801751A (zh) 2016-05-13 2018-01-16 塔維達治療公司 靶向構建體及其製劑
WO2017210246A2 (en) 2016-05-31 2017-12-07 Tarveda Therapeutics, Inc. Penicillamine conjugates and particles and formulations thereof
WO2017223085A2 (en) 2016-06-20 2017-12-28 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
US10858483B2 (en) 2016-07-06 2020-12-08 University Of Maryland, College Park Polyphosphazene polyelectrolytes and uses thereof
AU2017292934B9 (en) * 2016-07-07 2024-08-29 Bolt Biotherapeutics, Inc. Antibody adjuvant conjugates
KR102497742B1 (ko) 2016-08-30 2023-02-10 다나-파버 캔서 인스티튜트 인크. 약물 전달 조성물 및 그의 용도
WO2018045150A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
US11274115B2 (en) 2016-09-07 2022-03-15 Glaxosmithkline Biological Sa Imidazoquinoline derivatives and their use in therapy
US10954233B2 (en) 2016-09-09 2021-03-23 Novartis Ag Compounds and compositions as inhibitors of endosomal toll-like receptors
EP3532505A4 (en) 2016-10-25 2019-12-25 Urogen Pharma Ltd. BODY CAVES IMMUNODULATING TREATMENTS
WO2018079740A1 (ja) 2016-10-28 2018-05-03 東レ株式会社 癌の治療及び／又は予防用医薬組成物
CN116143678A (zh) 2016-11-14 2023-05-23 杭州多禧生物科技有限公司 偶联连接体，含有此连接体的细胞结合分子-药物偶联物及其制备和应用
WO2018112108A1 (en) 2016-12-13 2018-06-21 Bolt Biotherapeutics, Inc. Antibody adjuvant conjugates
EP3555330A4 (en) 2016-12-15 2020-05-13 Arconic Technologies LLC CORROSION RESISTANT ALUMINUM ALLOY
JP7128529B2 (ja) 2016-12-23 2022-08-31 アールイーエムディー バイオセラピューティクス，インコーポレイテッド プログラム死リガンド－１（ｐｄ－ｌ１）に結合する抗体を使用する免疫
RU2768404C2 (ru) 2016-12-23 2022-03-24 Ремд Биотерапьютикс, Инк. Иммунотерапия с применением антител, связывающих белок 1 программируемой смерти клеток (pd-1)
KR102619747B1 (ko) 2017-01-10 2023-12-29 넥타르 테라퓨틱스 Tlr 효현제 화합물의 다중-아암 중합체 컨쥬게이트 및 관련 면역 요법적 치료 방법
US20190336615A1 (en) 2017-01-27 2019-11-07 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
EP3576782A4 (en) 2017-02-02 2020-12-30 Silverback Therapeutics, Inc. COMPOSITIONS OF RECOMBINATION PRODUCT-PEPTIDE AND THEIR METHODS OF USE
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
WO2018156617A2 (en) 2017-02-22 2018-08-30 The Regents Of The University Of Michigan Compositions and methods for delivery of polymer / biomacromolecule conjugates
WO2018162446A1 (en) 2017-03-06 2018-09-13 Merck Patent Gmbh Aqueous anti-pd-l1 antibody formulation
EP3595668B1 (en) 2017-03-15 2021-07-21 Silverback Therapeutics, Inc. Benzazepine compounds, conjugates, and uses thereof
AU2018233403B2 (en) 2017-03-16 2021-02-25 Immunwork Inc. Linker units and molecular constructs comprising same
US11464854B2 (en) 2017-03-23 2022-10-11 Children's Medical Center Corporation Methods and compositions relating to adjuvants
CA3056816A1 (en) 2017-03-31 2018-10-04 Zymeworks Inc. Tumor antigen presentation inducer constructs and uses thereof
JP2020515629A (ja) 2017-04-04 2020-05-28 アヴィディア テクノロジーズ， インコーポレイテッド 免疫応答を誘導するためのペプチドベースのワクチン、それらの製造方法および使用
MX2019011957A (es) 2017-04-06 2019-11-07 Hangzhou Dac Biotech Co Ltd Conjugacion de un farmaco citotoxico con enlace bis.
US20180296685A1 (en) 2017-04-13 2018-10-18 Tarveda Therapeutics, Inc. Targeted constructs and formulations thereof
PT3609540T (pt) 2017-04-14 2023-03-01 Bolt Biotherapeutics Inc Método de síntese de imunoconjugado
CA3058944A1 (en) 2017-04-19 2018-10-25 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
CN108794467A (zh) 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
AR111760A1 (es) 2017-05-19 2019-08-14 Novartis Ag Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
EP4509132A3 (en) 2017-05-26 2025-11-19 The Johns Hopkins University Multifunctional antibody-ligand traps to modulate immune tolerence
EP3634401A1 (en) 2017-06-07 2020-04-15 Silverback Therapeutics, Inc. Antibody construct conjugates
AU2018279105A1 (en) 2017-06-07 2019-12-19 Silverback Therapeutics, Inc. Antibody conjugates of immune-modulatory compounds and uses thereof
CA3067268A1 (en) 2017-06-23 2018-12-27 Birdie Biopharmaceuticals, Inc. Crystalline resiquimod monosulfate anhydrate and its preparation and uses
AU2018290880A1 (en) 2017-06-28 2020-01-16 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for Dectin-2 stimulation and cancer immunotherapy
WO2019023622A1 (en) 2017-07-27 2019-01-31 The Board Of Trustees Of The Leland Stanford Junior University POLYMERIC NANOPARTICLES FOR IMPROVED ANTICANCERIC IMMUNOTHERAPY
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
US10457681B2 (en) 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
EP3668548A2 (en) 2017-08-17 2020-06-24 Nektar Therapeutics Immunotherapeutic tumor treatment method
US11713356B2 (en) 2017-10-13 2023-08-01 Ose Immunotherapeutics Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer
WO2019084060A1 (en) 2017-10-24 2019-05-02 Silverback Therapeutics, Inc. CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
WO2019099412A1 (en) 2017-11-14 2019-05-23 Dynavax Technologies Corporation Cleavable conjugates of tlr7/8 agonist compounds, methods for preparation, and uses thereof
WO2019118884A1 (en) 2017-12-15 2019-06-20 Silverback Therapeutics, Inc. Antibody construct-drug conjugate for the treatment of hepatitis
CA3086040A1 (en) 2017-12-19 2019-06-27 Blaze Bioscience, Inc. Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
KR20210006338A (ko) 2018-03-13 2021-01-18 오제 이뮈노테라프틱스 항-인간 SIRPa v1 항체의 이용 및 항-SIRPa v1 항체를 생산하는 방법
US20210009711A1 (en) 2018-03-14 2021-01-14 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
WO2019195278A1 (en) 2018-04-02 2019-10-10 Silverback Therapeutics, Inc. Alk5 inhibitors, conjugates, and uses thereof
CN108379591B (zh) 2018-04-03 2022-03-29 深圳大学 免疫激动剂靶向化合物的合成及其应用
WO2019209811A1 (en) 2018-04-24 2019-10-31 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (tlr7) agonists
WO2019222676A1 (en) 2018-05-17 2019-11-21 Bolt Biotherapeutics, Inc. Immunoconjugates
IL311536A (en) 2018-06-04 2024-05-01 Tufts College Binder-drug conjugates activated in the microenvironment and their related uses
CN114014932A (zh) 2018-07-09 2022-02-08 启德医药科技（苏州）有限公司 滋养层细胞表面抗原2(trop2)特异性抗体
AU2019311102A1 (en) 2018-07-24 2021-02-25 Torque Therapeutics, Inc TLR7/8 agonists and liposome compositions
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
AU2019330977A1 (en) 2018-08-29 2021-04-15 Bolt Biotherapeutics, Inc. Immunoconjugates targeting EGFR
US20210214354A1 (en) 2018-09-07 2021-07-15 Birdie Biopharmaceuticals, Inc. Imidazoquinoline compounds and uses thereof
AU2019337654A1 (en) 2018-09-12 2021-04-08 Silverback Therapeutics, Inc. Substituted benzazepine compounds, conjugates, and uses thereof
JP2022500414A (ja) 2018-09-12 2022-01-04 シルバーバック セラピューティックス インコーポレイテッド 免疫刺激性コンジュゲートにより疾患を処置する方法および組成物
WO2020056192A1 (en) 2018-09-12 2020-03-19 Silverback Therapeutics, Inc. Antibody conjugates of toll-like receptor agonists
WO2020056194A1 (en) 2018-09-12 2020-03-19 Silverback Therapeutics, Inc. Benzazepine compounds, conjugates, and uses thereof
EP3873532A1 (en) 2018-10-31 2021-09-08 Novartis AG Dc-sign antibody drug conjugates
EP3873938A1 (en) 2018-10-31 2021-09-08 Novartis AG Dc-sign antibody conjugates comprising sting agonists
HRP20230500T1 (hr) 2018-11-30 2023-07-21 Bristol-Myers Squibb Company Antitijelo koje sadrži c-terminalnu ekstenziju lakog lanca koja sadrži glutamin, njegovi konjugati, i postupci i primjene
KR20210102334A (ko) 2018-12-12 2021-08-19 브리스톨-마이어스 스큅 컴퍼니 트랜스글루타미나제 접합을 위해 변형된 항체, 그의 접합체, 및 방법 및 용도
WO2020139618A1 (en) 2018-12-26 2020-07-02 Birdie Biopharmaceuticals, Inc. Immune modulatory combinations and methods for treating cancers
JP2022516308A (ja) 2019-01-04 2022-02-25 アセンディス ファーマ オンコロジー ディヴィジョン エー／エス パターン認識受容体アゴニストのコンジュゲート
US20220089768A1 (en) 2019-01-04 2022-03-24 Trio Pharmaceuticals, Inc. Multi-specific protein molecules and uses thereof
JP7695885B2 (ja) 2019-02-12 2025-06-19 アンブルックス，インコーポレイテッド 抗体－ｔｌｒアゴニストコンジュゲートを含有する組成物、その方法、及び使用
WO2020190734A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting pd-l1
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
US20220226492A1 (en) 2019-03-15 2022-07-21 Bolt Biotherapeutics, Inc. Immunoconjugates Targeting HER2
WO2020190762A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Macromolecule-supported tlr agonists
CN113811299A (zh) 2019-03-15 2021-12-17 博笛生物科技有限公司 用于治疗癌症的免疫调控性组合物和方法
US20220152215A1 (en) 2019-03-15 2022-05-19 Bolt Biotherapeutics, Inc. Immunoconjugates Targeting CEA
BR112021019950A2 (pt) 2019-04-05 2021-12-07 Dren Bio Inc Métodos de esgotamento de agentes causadores de doenças por meio de anticorpo de fagocitose alvejada
WO2020252015A1 (en) 2019-06-10 2020-12-17 Sutro Biopharma, Inc. Immunomodulator antibody drug conjugates and uses thereof
KR20220034784A (ko) 2019-06-13 2022-03-18 볼트 바이오테라퓨틱스 인코퍼레이티드 아미노벤즈아제핀 화합물, 면역접합체, 및 이의 용도
CA3143156A1 (en) 2019-06-13 2020-12-17 Bolt Biotherapeutics, Inc. Macromolecule-supported aminobenzazepine compounds
US20220259202A1 (en) 2019-06-17 2022-08-18 Sutro Biopharma, Inc. 1-(4-(aminomethyl)benzyl)-2-butyl-2h-pyrazolo[3,4-c]quinolin-4-amine derivatives and related compounds as toll-like receptor (tlr) 7/8 agonists, as well as antibody drug conjugates thereof for use in cancer therapy and diagnosis
US20220249685A1 (en) 2019-06-19 2022-08-11 Silverback Therapeutics, Inc. Anti-mesothelin antibodies and immunoconjugates thereof
US20210139477A1 (en) 2019-07-16 2021-05-13 Silverback Therapeutics, Inc. Alk5 inhibitors, conjugates, and uses thereof
US11339159B2 (en) 2019-07-17 2022-05-24 Pfizer Inc. Toll-like receptor agonists
TW202120500A (zh) 2019-08-02 2021-06-01 美商梅爾莎納醫療公司 干擾素基因刺激蛋白（ｓｔｉｎｇ）激動劑化合物及用途
BR112022002720A2 (pt) 2019-08-15 2022-10-11 Silverback Therapeutics Inc Formulações de conjugados de benzazepinas e usos das mesmas
CA3148694A1 (en) 2019-09-03 2021-03-11 Romas Kudirka Aminoquinoline compounds, immunoconjugates, and uses thereof
JP2022547066A (ja) 2019-09-04 2022-11-10 ボルト バイオセラピューティクス、インコーポレーテッド 免疫結合体合成方法
CN114650844A (zh) 2019-09-23 2022-06-21 西托姆克斯治疗公司 抗cd47抗体、可活化抗cd47抗体及其使用方法
WO2021067261A1 (en) 2019-09-30 2021-04-08 The Board Of Trustees Of The Leland Stanford Junior University Knottin-immunostimulant conjugates and related compositions and methods
AU2020359446A1 (en) 2019-09-30 2022-04-21 Bolt Biotherapeutics, Inc. Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
WO2021067644A1 (en) 2019-10-01 2021-04-08 Silverback Therapeutics, Inc. Combination therapy with immune stimulatory conjugates
WO2021072203A1 (en) 2019-10-09 2021-04-15 Silverback Therapeutics, Inc. Tgfbetar1 inhibitor-asgr antibody conjugates and uses thereof
CA3154969A1 (en) 2019-10-25 2021-04-29 Romas Kudirka Macromolecule-supported thienoazepine compounds, and uses thereof
KR20220088901A (ko) 2019-10-25 2022-06-28 볼트 바이오테라퓨틱스 인코퍼레이티드 티에노아제핀 면역접합체, 및 이의 용도
EP4069683A1 (en) 2019-12-06 2022-10-12 Mersana Therapeutics, Inc. Dimeric compounds as sting agonists
KR20220114049A (ko) 2019-12-17 2022-08-17 화이자 인코포레이티드 Cd47, pd-l1에 특이적인 항체, 및 그의 용도
US20230101266A1 (en) 2019-12-31 2023-03-30 Genequantum Healthcare (Suzhou) Co., Ltd. Anti-trop2 antibodies, antibody-drug conjugates, and application of the same
US20230256108A1 (en) 2019-12-31 2023-08-17 Genequantum Healthcare (Suzhou) Co., Ltd. A drug conjugate and applications thereof
EP4093510A1 (en) 2020-01-21 2022-11-30 Bolt Biotherapeutics, Inc. Anti-pd-l1 antibodies
JP2023511363A (ja) 2020-01-21 2023-03-17 ボルト バイオセラピューティクス、インコーポレーテッド 坑ｐｄ－ｌ１抗体
US11179473B2 (en) 2020-02-21 2021-11-23 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
KR20220145871A (ko) 2020-02-25 2022-10-31 볼트 바이오테라퓨틱스 인코퍼레이티드 암 치료 방법
WO2021202921A1 (en) 2020-04-01 2021-10-07 Altimmune Uk Limited Imidazoquinoline-type compounds and uses thereof
CN115955980A (zh) 2020-04-10 2023-04-11 思进公司 电荷可变接头
CN115461122A (zh) 2020-05-01 2022-12-09 博尔特生物治疗药物有限公司 抗dectin-2抗体
EP4146282A1 (en) 2020-05-08 2023-03-15 Bolt Biotherapeutics, Inc. Elastase-substrate, peptide linker immunoconjugates, and uses thereof

Also Published As

Publication number Publication date
EP3484518A1 (en) 2019-05-22
EP3484518C0 (en) 2024-08-14
CN109843327A (zh) 2019-06-04
EP3484518A4 (en) 2020-04-22
JP2019520352A (ja) 2019-07-18
US20200206357A1 (en) 2020-07-02
WO2018009916A1 (en) 2018-01-11
AU2017292934B2 (en) 2024-04-04
CA3029902A1 (en) 2018-01-11
IL263616A (en) 2019-01-31
AU2017292934A1 (en) 2019-01-17
CN115317603A (zh) 2022-11-11
EP3484518B1 (en) 2024-08-14
JP2022037149A (ja) 2022-03-08
IL263616B1 (en) 2024-09-01
CN109843327B (zh) 2022-05-13
US11547761B1 (en) 2023-01-10
KR20190026761A (ko) 2019-03-13
US10675358B2 (en) 2020-06-09
US20190076547A1 (en) 2019-03-14
KR102590454B1 (ko) 2023-10-17
BR112019000071A2 (pt) 2019-07-02
KR20230149857A (ko) 2023-10-27
IL263616B2 (en) 2025-01-01
US11110178B2 (en) 2021-09-07
US20230111340A1 (en) 2023-04-13
KR102726248B1 (ko) 2024-11-05
AU2017292934B9 (en) 2024-08-29
JP7011764B2 (ja) 2022-01-27
JP2024001193A (ja) 2024-01-09

Similar Documents

Publication Publication Date Title
ES2990113T3 (es) Conjugados de adyuvantes de anticuerpos
ES3003787T3 (en) Immunoconjugates
US20200108151A1 (en) Antibody adjuvant conjugates
ES2939384T3 (es) Método de síntesis de inmunoconjugados
CA3151662A1 (en) Immunoconjugate synthesis method
HK40082669A (en) Antibody adjuvant conjugates
HK40006335B (zh) 抗体佐剂缀合物
HK40048016A (en) Immunoconjugates
HK40048016B (en) Immunoconjugates